We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Changing trends in aetiology‐based hospitalizations with end‐stage liver disease in the United States from 2016 to 2019.
- Authors
Kim, Donghee; Perumpail, Brandon J.; Alshuwaykh, Omar; Dennis, Brittany B.; Cholankeril, George; Ahmed, Aijaz
- Abstract
Backgrounds and Aims: A potent and safe antiviral agent may impact chronic hepatitis C (HCV)‐related end‐stage liver disease (ESLD). We assess aetiology‐based hospitalizations for ESLD in the United States, 2016–2019. Methods: We utilized the National Inpatient Sample (NIS) from 2016 to 2019. We defined ESLD as either decompensated cirrhosis or hepatocellular carcinoma, criteria obtained from the International Classification of Diseases, Tenth Revision. Results: National hospitalization rates for non‐alcoholic fatty liver disease (NAFLD) increased significantly from 67.1/100 000 persons in 2016 to 93.6 in 2019 with an average annual percentage change (AAPC) of 12.1%, while chronic hepatitis C (HCV) decreased significantly from 71.2/100 000 persons in 2016 to 58.5 in 2019 (−6.5% AAPC). Hospitalizations for ESLD in alcohol‐related liver disease (ALD) increased as well. Conclusions: Hospitalization rates for NAFLD‐ and ALD‐related ESLD increased steadily, while those for HCV‐related ESLD decreased during the direct‐acting antivirals era.
- Subjects
UNITED States; LIVER diseases; NON-alcoholic fatty liver disease; DISEASE progression; CHRONIC hepatitis C; HOSPITAL care
- Publication
Liver International, 2022, Vol 42, Issue 11, p2390
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.15381